Lilly Terminates Phase II Study of Alzheimer's Drug Due to Abnormal Liver Biochemical Tests - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Lilly Terminates Phase II Study of Alzheimer's Drug Due to Abnormal Liver Biochemical Tests
Eli Lilly has discontinued its Phase II study of the beta secretase (BACE) inhibitor, LY2886721, as a treatment for Alzheimer's disease. The decision was due to abnormal liver biochemical tests identified during routine monitoring.


Eli Lilly announced it has discontinued its Phase II study, which investigated the company’s beta secretase (BACE) inhibitor, LY2886721, as a once-daily treatment for slowing the progression of Alzheimer’s disease. The decision to terminate the study was because of abnormal liver biochemical tests identified during routine monitoring. Clinical study investigators have been notified and Lilly will continue to monitor all participants with abnormal liver biochemical tests.

"While stopping this Phase II study for our BACE inhibitor is disappointing, patient safety is of utmost importance to Lilly," said Jan M. Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories in a press release. "Discovering and developing medicines for devastating diseases like Alzheimer's is fraught with many challenges, but Lilly's 25-year commitment to bringing medicines to the millions of Alzheimer's disease patients who are waiting will not wane."

Lilly believes that the abnormal liver biochemical tests observed in this study are not related to the BACE mechanism and will continue development of other BACE inhibitors for Alzheimer’s disease. Data will be evaluated before the company determines next steps for the LY2886721 clinical development program.

The company expects to incur a financial charge as a result of terminating this trial. However, the amount of this charge is not expected to change the company's previously-issued 2013 financial guidance.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here